Oregon's first licensed service center opened to clients in the summer of 2023, which makes the state's program a little over three years old. In that time it has gone from an untested idea to an operating industry with thousands of clients, and it has also lost a large share of its service centers and run into a budget shortfall of its own. This post pulls together what the state's published data and budget documents show as of November 2026.
Clients and centers
The Oregon Health Authority (OHA) began collecting client data from service centers on January 1, 2025. In 2025, centers reported serving 5,935 clients. In the first half of 2026 they reported 2,172 clients, plus another 430 who received services but opted out of data reporting, for about 2,600 in all. That's fewer than in the first half of 2025, when centers reported 3,267 clients, though the comparison is rough because opt-outs weren't counted separately in 2025. Counting the years before data collection began, OHA estimates that more than 22,000 clients have been served in Oregon since 2023. As of October 1, 2026, licensed service centers had sold more than 50,000 psilocybin products for administration sessions, a figure that OHA notes may include second doses.
A large share of clients come from outside the state. In OHA's data through March 31, 2026, 2,114 clients had traveled to Oregon from another state and 200 from another country, compared with 1,516 who traveled from within Oregon. Another 485 didn't answer the question.
OHA also publishes safety reports. Of the 5,935 clients served in 2025, centers reported 7 severe behavioral reactions and 2 severe medical reactions that required transport to a hospital. From January 2023 through July 2026, there were 32 reports of emergency services being contacted, and no psilocybin product has been recalled.
The number of service centers has moved in the other direction. Of the 39 service center licenses OHA has issued, 20 were approved and active as of July 23, 2026, and OHA reports that over a third of centers have surrendered their licenses or not renewed them. Closures in 2026 included the Cora Center in Portland in January and InnerTrek's Portland center in June, which InnerTrek attributed to its lease ending. Facilitator licensing has held up better. OHA had issued 641 facilitator licenses in all, with 379 approved as of July 23, 2026, and it reports a steady increase in applications since 2025. Because Oregon facilitators can supervise clients only at a licensed service center, the shrinking number of centers limits where all of those facilitators can work.
Prices and the cost of operating
Psilocybin services in Oregon are expensive for clients. In a study published in Health Affairs Scholar in October 2026, researchers called 15 of the state's active service centers posing as prospective clients. They found a median price of $1,900 for a session, and none of the centers accepted insurance.
Those prices reflect high operating costs. A service center pays a $10,000 annual license fee ($5,000 for qualifying nonprofits and reduced-fee applicants), on top of rent, staffing, and insurance. In its own budget documents, OHA lists the constraints licensees face: local ordinances that prohibit psilocybin businesses in some cities and counties, restrictive zoning, and high costs for insurance, banking, and tax filing, all tied to psilocybin's status as a Schedule I substance under federal law. A New York Times reporter covering the industry said on Oregon Public Broadcasting in January 2026 that centers' insurance runs about three times what other health businesses pay.
The program's own budget
The state program is under financial pressure too. Oregon's psilocybin program runs almost entirely on licensing fees, and for the 2025 to 2027 budget period it received no money from the state's General Fund. In August 2026, OHA projected that without a fee increase the program would end the period about $3.9 million short. It had already cut its staff from 23 full-time positions to 17, which it describes as the minimum needed to carry out the law. On September 1, 2026, the program merged with the Oregon Medical Marijuana Program into a new Medical Cannabis & Psilocybin (MCAP) Section, a change OHA expects to save a small amount of money.
To close the gap, OHA proposed in 2026 to raise license fees sharply starting in 2027 and to eliminate reduced fees for low-income, veteran, and nonprofit applicants. Under the proposal, a facilitator who qualified for the reduced fee would have gone from $1,000 a year to $4,000, a reduced-fee service center from $5,000 to $20,000, and a worker permit from $25 to $200. The Rules Advisory Committee was unanimously opposed, arguing that higher fees would push licensees out of the program, shrink its revenue further, and make services less affordable for clients. In October 2026, OHA decided not to adopt the fee increases, and it wrote that raising fees may be counterproductive. Current fees stay in place for now, and OHA plans a separate rulemaking, unrelated to fees, with rules taking effect January 15, 2027.
That leaves the underlying shortfall unresolved. OHA's October 2026 budget overview says that without a significant increase in licensees and changes to the statute, the program's ability to meet its legal requirements will depend on General Fund money or new sources of revenue. The 2027 legislative session is the next place that question is likely to be taken up.
The legislature has also been changing what the program can be. A 2025 law, House Bill 2387, created dual licensure, which lets licensed facilitators who also hold licenses as counselors, therapists, psychologists, physicians, nurses, naturopaths, pharmacists, or social workers provide health and behavioral health services during preparation and integration sessions. A 2026 law, House Bill 4040, added occupational therapists and physical therapists. OHA reports that the steady rise in facilitator applications began after House Bill 2387 passed. The federal picture may matter as well. Compass Pathways completed its application to the Food and Drug Administration (FDA) in November 2026 for a psilocybin drug for treatment-resistant depression, and OHA has noted that an approved drug would need a clinical framework of licensed prescribers, some of whom are already dual-licensed facilitators in Oregon. How a clinical psilocybin product would sit alongside Oregon's existing model is an open question.
For facilitators and people considering training, the overall picture is a program with several thousand clients a year, a large and growing pool of licensed facilitators, a shrinking number of centers where they can work, and a regulator that is short of money and has decided against solving that with higher fees. The next quarterly data release, the January 2027 rule changes, and the 2027 legislative session are the developments to watch.
Editor's note. Sources, accessed November 17, 2026: Oregon Health Authority, Oregon Psilocybin Services Budget Information, August 2026 (client origins, safety reports, emergency contacts, recalls, license counts as of July 23, 2026, service center surrenders and non-renewals, budget shortfall projection, staffing, proposed fee increases and Rules Advisory Committee response, House Bills 2387 and 4040, the merger); OHA, Medical Cannabis & Psilocybin Budget Information, October 2026 (products sold, first center opening, licensee constraints, decision not to adopt fee increases, January 15, 2027 rulemaking, program sustainability); OHA, 2025 Year-End Data Summary and quarterly data files through the second quarter of 2026 (clients served and opt-outs); OHA, Psilocybin Services Data Dashboard, second-quarter 2026 archive; Oregon Administrative Rules 333-333-4060 (current license fees); Adams et al., "Am I a candidate for magic mushrooms? A mystery shopper study of Oregon psilocybin service centers," Health Affairs Scholar, October 12, 2026; Willamette Week, January 5 and June 30, 2026 (Cora Center and InnerTrek closures); Oregon Public Broadcasting, Think Out Loud, January 22, 2026 (insurance costs); Compass Pathways, press release, November 2026 (new drug application). Client totals for 2026 combine reported clients and clients who opted out of reporting.